WuXi Biologics Earns Third Consecutive MSCI AAA ESG Rating
- WuXi Biologics received an MSCI AAA ESG rating for the third year.
- MSCI ESG Ratings cover over 17,000 issuers and 999,000 securities.
- WuXi Biologics supports 864 client projects, including 24 in commercial manufacturing.
- The company’s emissions-reduction targets are approved by the Science Based Targets initiative.
MSCI AAA ESG Rating
WuXi Biologics has been awarded the MSCI AAA ESG rating for the third consecutive year, highlighting its leadership in sustainability. This rating places the company among a select group recognized for exceptional ESG performance, particularly in climate change, product safety, human capital development, and corporate governance.
Global ESG Insights
MSCI ESG Ratings, covering over 17,000 issuers and 999,000 securities worldwide, provide critical insights for investment decisions by assessing companies' resilience to industry-specific sustainability risks and opportunities.
Commitment to Sustainability
Aligned with the United Nations Sustainable Development Goals, WuXi Biologics actively participates in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative. The company's emissions-reduction targets have been approved by the Science Based Targets initiative.
Recognition and Awards
WuXi Biologics has received numerous accolades for its sustainability efforts, including an EcoVadis Platinum Medal, listing in the Dow Jones Sustainability Indices, and recognition in the CDP Water Security “A list.” It has also been awarded a leadership-level score by CDP Climate Change and recognized by Sustainalytics and FTSE4Good Index Series.
Operational Scale
With over 12,000 employees across multiple countries, WuXi Biologics supports 864 integrated client projects, including 24 in commercial manufacturing, leveraging its expertise to provide efficient biologics solutions.
Source: WuXi